

Reference:	FOI.1986.19
Subject:	Juvenile idiopathic arthritis
Date of Request:	19 November 2019

Requested:

I Would like to understand how patients with juvenile idiopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile idiopathic arthritis have been treated with:

Humira (adalimumab)
Amgevita (adalimumab)
Imraldi (adalimumab)
Hyrimoz (adalimumab)
Hulio (adalimumab)
Tocilizumab
Abatacept
Enbrel (etanercept)
Erelzi (etanercept)
Benepali (etanercept)
Golimumab
Remicade (infliximab)
Remsima (infliximab)
Inflectra (infliximab)
Flixabi (infliximab)
Canakinumab

Response:

The UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.